WINTON GROUP Ltd Purchases 335,269 Shares of Roivant Sciences Ltd. $ROIV

Key Points

• WINTON GROUP Ltd increased its stake in Roivant Sciences by 161.1% in Q3, buying 335,269 shares to hold 543,333 shares valued at $8.22 million (about 0.08% of the company).
• Significant insider selling: Director Daniel Allen Gold sold 375,784 shares (~$9.96M) and CEO Eric Venker sold 200,000 shares (~$5.30M) on Feb. 13, and insiders disposed of 13,318,014 shares worth $315.7M in the last quarter (insiders now own 10.8%).
• Analysts are broadly bullish with multiple price-target raises—Goldman Sachs to $33 and Citigroup to $35—and Roivant has a consensus rating of "Moderate Buy" and a consensus price target of $28.81 (8 Buy, 1 Hold, 1 Sell).

WINTON GROUP Ltd grew its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 161.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 543,333 shares of the company's stock after acquiring an additional 335,269 shares during the quarter. WINTON GROUP Ltd owned 0.08% of Roivant Sciences worth $8,221,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Jones Financial Companies Lllp lifted its position in Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company's stock worth $25,000 after buying an additional 1,148 shares in the last quarter. Bessemer Group Inc. grew its holdings in shares of Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Roivant Sciences by 204.2% in the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company's stock valued at $65,000 after acquiring an additional 3,882 shares during the last quarter. Aster Capital Management DIFC Ltd increased its position in shares of Roivant Sciences by 75.8% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company's stock valued at $67,000 after acquiring an additional 1,900 shares during the last quarter. Finally, Orion Porfolio Solutions LLC bought a new stake in Roivant Sciences during the second quarter worth about $117,000. 64.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. The Goldman Sachs Group raised their price target on Roivant Sciences from $24.00 to $33.00 and gave the company a "buy" rating in a research note on Monday, December 15th. Citigroup raised their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a research note on Tuesday, February 10th. Weiss Ratings downgraded shares of Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a report on Monday, February 9th. Jefferies Financial Group reiterated a "buy" rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, TD Cowen reissued a "buy" rating on shares of Roivant Sciences in a research report on Wednesday. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Roivant Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $28.81.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Daniel Allen Gold sold 375,784 shares of the firm's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $26.50, for a total transaction of $9,958,276.00. Following the completion of the sale, the director directly owned 15,127,329 shares in the company, valued at $400,874,218.50. This trade represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the business's stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $26.49, for a total value of $5,298,000.00. Following the sale, the chief executive officer owned 1,654,597 shares of the company's stock, valued at approximately $43,830,274.53. This represents a 10.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 13,318,014 shares of company stock worth $315,727,023. 10.80% of the stock is owned by corporate insiders.

Roivant Sciences Price Performance

ROIV stock opened at $28.78 on Monday. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $30.03. The stock has a market cap of $20.60 billion, a price-to-earnings ratio of -24.60 and a beta of 1.17. The company has a fifty day moving average price of $24.56 and a two-hundred day moving average price of $20.15.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.